Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Next Previous
Trial Profile

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entrectinib (Primary) ; Entrectinib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Anaplastic large cell lymphoma; Brain metastases; Cholangiocarcinoma; CNS cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Solid tumours; Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms STARTRK-2
  • Sponsors Roche

Most Recent Events

  • 09 Jan 2025 Planned End Date changed from 1 Apr 2025 to 31 Dec 2025.
  • 09 Jan 2025 Planned primary completion date changed from 31 Dec 2024 to 30 Jun 2025.
  • 24 Apr 2024 This trial has been completed in Belgium according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top